RxDoctor Payments Data

Vidya Sagar, MD

Nephrology · Clearwater, FLNPI 1457376683

Payments from drug & device makers

$12,057in general payments, 2019–2025

Across 431 payments — averaging $27.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • AstraZeneca$2K
  • Travere Therapeutics, Inc.$905
  • Bayer$736
  • Novo Nordisk$717
  • Mallinckrodt Hospital Products Inc.$670
  • plus $4K from 20 others

What the payments were for

  • Consulting fees$1501%
  • Speaking & faculty fees$1,54913%
  • Food & beverage$10,27985%
  • Education$781%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,057 in reported general payments places this provider in the 80th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$391,915
Medicare patients
617
Services billed
3,006

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide191$268,355
FarxigaDapagliflozin Propanediol234$244,051
JardianceEmpagliflozin116$167,485
RybelsusSemaglutide43$78,224
RayaldeeCalcifediol18$37,129
XphozahTenapanor Hcl11$34,804
TrulicityDulaglutide18$33,691
Cinacalcet Hcl71$20,180
Sevelamer Carbonate66$15,544
Paricalcitol83$8,285
Terazosin Hcl252$6,310
Midodrine Hcl21$4,732
Metoprolol Succinate244$3,998
Calcitriol191$3,392
Torsemide169$3,378

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$717$346,579234 claims
AstraZenecaFarxiga$2,039$244,051234 claims
Boehringer IngelheimJardiance$358$167,485116 claims
OPKO Pharmaceuticals, LLCRayaldee$527$37,12918 claims
Lilly USA, LLCTrulicity$628$33,69118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 756 nephrology providers in Florida.

Other nephrology in Clearwater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →